Optimization of GPR40 agonists for type 2 diabetes

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 517-521

  Liu, Jiwen ^a   Wang, Yingcai ^a   Ma, Zhihua ^a   Schmitt, Mike ^a   Zhu, Liusheng ^a   Brown, Sean P ^a   Dransfield, Paul J ^a   Sun, Ying ^a   Sharma, Rajiv ^a   Guo, Qi ^a   Zhuang, Run ^a   Zhang, Jane ^a   Luo, Jian ^a   Tonn, George R ^a   Wong, Simon ^a   Swaminath, Gayathri ^a   Medina, Julio C ^a   Lin, Daniel C H ^a   Houze, Jonathan B ^a  

^a AMGEN INC   (United States)

Author keywords

agonist; FFA1; FFAR1; GPCR; GPR40; insulin secretagogue; type II diabetes

Indexed keywords

AM 4668; ANTIDIABETIC AGENT; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; HEMOGLOBIN A1C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN RELEASE; MACACA FASCICULARIS; MICHAEL ADDITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT;

EID: 84900430969     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400501x     Document Type: Article

References (22)

1. Wajchenberg, B. L. β-Cell failure in diabetes and preservation by clinical treatment Endocr. Rev. 2007, 28, 187-218
2. Maedler, K.; Carr, R. D.; Bosco, D.; Zuellig, R. A.; Berney, T.; Donath, M. Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets J. Clin. Endocrinol. Metab. 2005, 90, 501-506
3. Edfalk, S.; Steneberg, P.; Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion Diabetes 2008, 57, 2280-2287
4. Morgan, N. G.; Dhayal, S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell Biochem. Pharmacol. 2009, 78, 1419-1427
5. Steneberg, P.; Rubins, N.; Bartoov-Shifman, R.; Walker, M. D.; Edlund, H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse Cell Metab. 2005, 1, 245-258
6. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Eillis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R., Jr; Shabon, U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 2003, 278, 11303-11311
7. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 2010, 1, 290-294
8. Sasaki, S.; Kitamura, S.; Negoro, N.; Suzuki, M.; Tsujihata, Y.; Suzuki, N.; Santou, T.; Kanzaki, N.; Harada, M.; Tanaka, Y.; Kobayashi, M.; Tada, N.; Funami, M.; Tanaka, T.; Yamamoto, Y.; Fukatsu, K.; Yasuma, T.; Momose, Y. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists J. Med. Chem. 2011, 54, 1365-1378
9. Naik, H.; Vakilynejad, M.; Wu, J.; Viswanathan, P.; Dote, N.; Higuchi, T.; Leifke, E. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers J. Clin. Pharmacol. 2012, 52, 1007-1016
10. Walsh, S. P.; Severino, A.; Zhou, C.; He, J.; Liang, G.-B.; Tan, C. P.; Cao, J.; Eiermann, G. J.; Xu, L.; Salituro, G.; Howard, A. D.; Mills, S. G.; Yang, L. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists Bioorg. Med. Chem. Lett. 2011, 21, 3390-3394
11. Alquier, T.; Poitout, V. GPR40: good cop, bad cop? Diabetes 2009, 58, 1035-1036
12. Stoddart, L. A.; Smith, N. J.; Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions Pharmacol. Rev. 2008, 60, 405-417
13. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 Nature 2003, 422, 173-176
14. Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; Liu, J.; Medina, J. C.; Reagan, J. D.; Luo, J.; Tonn, G.; Zhang, J.; Lu, J. Y.-L.; Chen, M.; Lopez, E.; Nguyen, K.; Yang, L.; Tang, L.; Tian, H.; Shuttleworth, S. J.; Lin, D. C.-H. AMG 837: A potent, orally bioavailable GPR40 agonist Bioorg. Med. Chem. Lett. 2012, 22, 1267-1270
15. Lin, D. C.-H.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; Tran, T.; Lopez, E.; Lu, J. Y. L.; Li, X. N.; Tang, L.; Tonn, G. R.; Swaminath, G.; Reagan, J. D.; Chen, J.-L.; Tian, H.; Lin, Y.-J.; Houze, J. B.; Luo, J. AMG 837: A novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents PLoS One 2011, 6, e27270
16. Burant, C. F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad, M.; Xie, B.; Leifke, E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial Lancet 2012, 379, 1403-1411
17. Takeda news release. http://www.takeda.com/news/2013/20130516-5780.html.
18. Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs Biochem. Biophys. Res. Commun. 2003, 301, 406-410
19. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 2010, 1, 420-434
20. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999, 16, 1514-1519
21. Mulzer, J.; Zuhse, R.; Schmiechen, R. Enantioselective synthesis of the antidepressant Rolipram by Michael addition to a nitroolefin Angew. Chem., Int. Ed. 1992, 31, 870-872
22. Mukaiyama, T.; Hoshino, T. The reactions of primary nitroparaffins with isocyanates J. Am. Chem. Soc. 1960, 82, 5339-5342